OpportunityTitle: The Use of Polyethylene Glycol in the Pediatric Population (R01)
AdditionalInformationOnEligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are  eligible to apply.    Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.    Foreign components, as defined in the HHS Grants Policy Statement, are allowed.
Description: The purpose of the proposed study is to better understand the extent of pediatric absorption of low molecular weight species that may be found in PEG 3350 products (e.g., ethylene and diethylene glycol). PEG 3350 products are used in the treatment of constipation. These low molecular weight species may be absorbed by children taking PEG 3350 products, potentially leading to adverse events. This is an important first step needed to begin to understand if PEG 3350 use contributes to adverse events in children due to the absorption of these species.
GrantorContactEmailDescription: lisa.ko@fda.hhs.gov
GrantorContactText: Lisa Ko &lt;br/&gt;Grants Management Specialist